Our previous studies showed that inhibition of ceramide glycosylation, either by silencing of GCS expression with MBO-asGCS or by inhibiting GCS activity with PDMP, increased cellular ceramide levels and restored wt p53 expression as well as p53-dependent apoptosis in cancer cells carrying p53 deletion mutants [32, 33]. This evidence concerns the gene UGCG and cancer.